Granulocyte transfusions for preventing infections in patients with neutropenia or neutrophil dysfunction

Paulus, Ulrike; Massey, Edwin; Dorée, Carolyn; Brunskill, Susan J; Hyde, Chris; Lucas, Geoff; Marks, David I.; Navarrete, C.; Stanworth, Simon

doi:10.1002/14651858.cd005341

Cited by 3 publications

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DescriptionData frame containing the results of 50 trials of 8 thrombolytic drugs (streptokinase, SK; alteplase, t-PA; accelerated alteplase, Acc t-PA; streptokinase plus alteplase, SK+tPA; reteplase, r-PA; tenocteplase, TNK; urokinase, UK; anistreptilase, ASPAC) plus per-cutaneous transluminal coronary angioplasty (PTCA)(Boland et al 2003;Lu and Ades 2006;. The number of deaths in 30 or 35 days following acute myocardial infarction are recorded.Data frame containing the number of deaths in 6 trials comparing transfusion of granulocytes (white blood cells) to control(Stanworth et al 2005).…”

mentioning

confidence: 99%

multinma: Bayesian Network Meta-Analysis of Individual and Aggregate Data

Phillippo

2020

CRAN: Contributed Packages

View full text Add to dashboard Cite

mentioning

confidence: 99%

multinma: Bayesian Network Meta-Analysis of Individual and Aggregate Data

Phillippo

2020

CRAN: Contributed Packages

View full text Add to dashboard Cite

Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy

Gafter‐Gvili

Fraser²,

Paul

et al. 2012

Cochrane Database of Systematic Reviews

216

172

View full text Add to dashboard Cite

show abstract

Granulocyte transfusions for preventing infections in people with neutropenia or neutrophil dysfunction

Estcourt

Stanworth

Dorée

et al. 2015

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Background Despite modern antimicrobials and supportive therapy, bacterial and fungal infections are still major complications in people with prolonged disease-related or therapy-related neutropenia. Since the late 1990s there has been increasing demand for donated granulocyte transfusions to treat or prevent severe infections in people who lack their own functional granulocytes. This is an update of a Cochrane review first published in 2009. Objectives To determine the effectiveness and safety of prophylactic granulocyte transfusions compared with a control population not receiving this intervention for preventing all-cause mortality, mortality due to infection, and evidence of infection due to infection or due to any other cause in people with neutropenia or disorders of neutrophil function. Search methods We searched for randomised controlled trials (RCTs) and quasi-RCTs in the Cochrane Central Register of Controlled Trials (Cochrane Library 2015, Issue 3), MEDLINE (from 1946), EMBASE (from 1974), CINAHL (from 1937), the Transfusion Evidence Library (from 1980) and ongoing trial databases to April 20 2015. Selection criteria Randomised controlled trials (RCTs) and quasi-RCTs comparing people receiving granulocyte transfusions to prevent the development of infection with a control group receiving no granulocyte transfusions. Neonates are the subject of another Cochrane review and were excluded from this review. There was no restriction by outcomes examined, but this review focuses on mortality, mortality due to infection and adverse events. Data collection and analysis We used standard methodological procedures expected by The Cochrane Collaboration. Main results Twelve trials met the inclusion criteria. One trial is still ongoing, leaving a total of 11 trials eligible involving 653 participants. These trials were conducted between 1978 and 2006 and enrolled participants from fairly comparable patient populations. None of the studies included people with neutrophil dysfunction. Ten studies included only adults, and two studies included children and adults. Ten of these studies contained separate data for each arm and were able to be critically appraised. One study re-randomised people and therefore quantitative analysis was unable to be performed. Overall, the quality of the evidence was very low to low across different outcomes according to GRADE methodology. This was due to many of the studies being at high risk of bias, and many of the outcome estimates being imprecise. All-cause mortality was reported for nine studies (609 participants). There was no difference in all-cause mortality over 30 days between people receiving prophylactic granulocyte transfusions and those that did not (seven studies; 437 participants; RR 0.92, 95% CI 0.63 to 1.36, very low-quality evidence). Mortality due to infection was reported for seven studies (398 participants). There was no difference in mortality due to infection over 30 days between people receiving prophylactic granulocyte transfusions and those that did no...

show abstract

Granulocyte transfusions for preventing infections in patients with neutropenia or neutrophil dysfunction

Cited by 3 publications

References 17 publications

multinma: Bayesian Network Meta-Analysis of Individual and Aggregate Data

multinma: Bayesian Network Meta-Analysis of Individual and Aggregate Data

Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy

Granulocyte transfusions for preventing infections in people with neutropenia or neutrophil dysfunction

Contact Info

Product

Resources

About